Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Dec;2(4):689-92.
doi: 10.2147/opth.s3965.

Topical nepafenac in the treatment of diabetic macular edema

David Callanan  1 , Patrick Williams
Affiliations

Topical nepafenac in the treatment of diabetic macular edema

David Callanan et al. Clin Ophthalmol. 2008 Dec.

Abstract

Purpose: To determine the safety and efficacy of topical nepafenac 0.1% in the treatment of diabetic macular edema.

Methods: A consecutive case series was performed of patients treated with nepafenac monotherapy twice daily for diabetic macular edema. Visual acuities (VA) at baseline and final visit were recorded. Foveal thickness, based on optical coherence tomography, was also recorded.

Results: Six eyes of 5 patients were included in this study. Median initial Snellen vision was 20/100 (range, 20/40-20/400). After a mean of 210 days (range, 182-259), median final VA was 20/75 (range, 20/40-20/400). Four eyes gained vision and two eyes maintained vision. Mean pre-treatment vision was 0.78 logMAR and final VA was 0.67 logMAR, for a statistically significant improvement (p < 0.05). Mean initial foveal thickness was 417 microns (range, 286-599). After a mean of 178 days (range, 91-259), mean foveal thickness was 267 microns (range, 158-423), showing a statistically significant improvement (p < 0.05). Each eye had an improvement in foveal thickness.

Conclusion: The results from these 6 eyes suggest that nepafenac 0.1% may have activity against diabetic macular edema and warrants further investigation.

Keywords: NSAIDs; diabetes; diabetic macular edema; inflammation; macular edema; nepafenac.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A OCT image of left eye in Patient #3 at baseline. Central subfield thickness was 517 μm and total volume was 9.02 mm3. B OCT image of left eye in Patient #3 after 259 days of nepafenac treatment. Central subfield thickness was 158 μm and total volume was 7.35 mm3.
See this image and copyright information in PMC

References

    1. [EDTRS] Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103:1796–806. - PubMed
    1. Gibran SK, Khan K, Jungkim S, et al. Optical coherence tomographic pattern may predict visual outcome after intravitreal triamcinolone for diabetic macular edema. Ophthalmology. 2007;114:890–4. - PubMed
    1. Gillies MC, Sutter FK, Simpson JM, et al. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology. 2006;113:1533–8. - PubMed
    1. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina. 2006;26:999–1005. - PubMed
    1. Kapin MA, Yanni JM, Brady MT, et al. Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac. Inflammation. 2003;27:281–91. - PubMed